Price T Rowe Associates Inc Cullinan Oncology, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 20,799 shares of CGEM stock, worth $373,342. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,799
Previous 22,842
8.94%
Holding current value
$373,342
Previous $390,000
6.92%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding CGEM
# of Institutions
140Shares Held
65.9MCall Options Held
77.2KPut Options Held
15.9K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$137 Million21.42% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$103 Million3.07% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$63.7 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$61.3 Million15.23% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.28MShares$58.9 Million1.2% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $819M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...